Cargando…
A randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the EPIC study
PURPOSE: Clonidine may help prevent cardiac complications in patients undergoing non-cardiac surgery and receiving chronic beta-blocker therapy. We conducted a multicentre pilot randomized trial to estimate recruitment rates for a full-scale trial and to assess the safety and tolerability of combini...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194011/ https://www.ncbi.nlm.nih.gov/pubmed/25189430 http://dx.doi.org/10.1007/s12630-014-0226-6 |
_version_ | 1782339070678007808 |
---|---|
author | Wijeysundera, Duminda N. Choi, Peter T. Badner, Neal H. Brasher, Penelope M. Dresser, George K. Delgado, Diego H. Beattie, W. Scott |
author_facet | Wijeysundera, Duminda N. Choi, Peter T. Badner, Neal H. Brasher, Penelope M. Dresser, George K. Delgado, Diego H. Beattie, W. Scott |
author_sort | Wijeysundera, Duminda N. |
collection | PubMed |
description | PURPOSE: Clonidine may help prevent cardiac complications in patients undergoing non-cardiac surgery and receiving chronic beta-blocker therapy. We conducted a multicentre pilot randomized trial to estimate recruitment rates for a full-scale trial and to assess the safety and tolerability of combining clonidine with chronic beta-blockade. METHODS: Patients who were at elevated perioperative cardiac risk, receiving chronic beta-blockade, and scheduled for major non-cardiac surgery were recruited in a blinded (participants, clinicians, outcome assessors) placebo-controlled randomized trial at three Canadian hospitals. Participants were randomized to clonidine (0.2 mg oral tablet one hour before surgery, plus 0.2 mg·day(−1) transdermal patch placed one hour before surgery and removed four days after surgery or hospital discharge, whichever came first) or matching placebo. Feasibility was evaluated based on recruitment rates, with each centre being required to recruit 50 participants within 12-18 months. Additionally, we reviewed study drug withdrawals and safety outcomes, including clinically significant hypotension or bradycardia. RESULTS: Eighty-two of the 168 participants were randomized to receive clonidine and 86 to receive placebo. The average time to recruit 50 participants at each centre was 14.3 months. Six patients (7%) withdrew from clonidine, while four (5%) withdrew from placebo. Based on qualitative review, there were no major safety concerns related to clonidine. There was a moderate overall rate of cardiac morbidity, with 18 participants (11%) suffering postoperative myocardial infarction. CONCLUSION: This pilot randomized trial confirmed the feasibility, safety, and tolerability of a full-scale trial of oral and transdermal clonidine for reducing the risk of cardiac complications during non-cardiac surgery. This trial was registered at www.clinicaltrials.gov: NCT00335582. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12630-014-0226-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4194011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-41940112014-10-15 A randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the EPIC study Wijeysundera, Duminda N. Choi, Peter T. Badner, Neal H. Brasher, Penelope M. Dresser, George K. Delgado, Diego H. Beattie, W. Scott Can J Anaesth Reports of Original Investigations PURPOSE: Clonidine may help prevent cardiac complications in patients undergoing non-cardiac surgery and receiving chronic beta-blocker therapy. We conducted a multicentre pilot randomized trial to estimate recruitment rates for a full-scale trial and to assess the safety and tolerability of combining clonidine with chronic beta-blockade. METHODS: Patients who were at elevated perioperative cardiac risk, receiving chronic beta-blockade, and scheduled for major non-cardiac surgery were recruited in a blinded (participants, clinicians, outcome assessors) placebo-controlled randomized trial at three Canadian hospitals. Participants were randomized to clonidine (0.2 mg oral tablet one hour before surgery, plus 0.2 mg·day(−1) transdermal patch placed one hour before surgery and removed four days after surgery or hospital discharge, whichever came first) or matching placebo. Feasibility was evaluated based on recruitment rates, with each centre being required to recruit 50 participants within 12-18 months. Additionally, we reviewed study drug withdrawals and safety outcomes, including clinically significant hypotension or bradycardia. RESULTS: Eighty-two of the 168 participants were randomized to receive clonidine and 86 to receive placebo. The average time to recruit 50 participants at each centre was 14.3 months. Six patients (7%) withdrew from clonidine, while four (5%) withdrew from placebo. Based on qualitative review, there were no major safety concerns related to clonidine. There was a moderate overall rate of cardiac morbidity, with 18 participants (11%) suffering postoperative myocardial infarction. CONCLUSION: This pilot randomized trial confirmed the feasibility, safety, and tolerability of a full-scale trial of oral and transdermal clonidine for reducing the risk of cardiac complications during non-cardiac surgery. This trial was registered at www.clinicaltrials.gov: NCT00335582. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12630-014-0226-6) contains supplementary material, which is available to authorized users. Springer US 2014-09-05 2014 /pmc/articles/PMC4194011/ /pubmed/25189430 http://dx.doi.org/10.1007/s12630-014-0226-6 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Reports of Original Investigations Wijeysundera, Duminda N. Choi, Peter T. Badner, Neal H. Brasher, Penelope M. Dresser, George K. Delgado, Diego H. Beattie, W. Scott A randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the EPIC study |
title | A randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the EPIC study |
title_full | A randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the EPIC study |
title_fullStr | A randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the EPIC study |
title_full_unstemmed | A randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the EPIC study |
title_short | A randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the EPIC study |
title_sort | randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the epic study |
topic | Reports of Original Investigations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194011/ https://www.ncbi.nlm.nih.gov/pubmed/25189430 http://dx.doi.org/10.1007/s12630-014-0226-6 |
work_keys_str_mv | AT wijeysunderadumindan arandomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy AT choipetert arandomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy AT badnernealh arandomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy AT brasherpenelopem arandomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy AT dressergeorgek arandomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy AT delgadodiegoh arandomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy AT beattiewscott arandomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy AT wijeysunderadumindan randomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy AT choipetert randomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy AT badnernealh randomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy AT brasherpenelopem randomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy AT dressergeorgek randomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy AT delgadodiegoh randomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy AT beattiewscott randomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy |